akash.verma@cenmed.com
(732) 447-1115-
E654643-1mlEdasalonexent (CAT-1004) is an orally bioavailable NF-κB inhibitor.In VitroEdasalonexent is an orally administered small molecule in which salicylic acid and docosahexaenoic acid (DHA) are covalently conjugated through an ethylenediamine linker and -
E646583-5mgEdasalonexent (CAT-1004) is an orally bioavailable NF-κB inhibitor.In VitroEdasalonexent is an orally administered small molecule in which salicylic acid and docosahexaenoic acid (DHA) are covalently conjugated through an ethylenediamine linker and -
E646583-50mgEdasalonexent (CAT-1004) is an orally bioavailable NF-κB inhibitor.In VitroEdasalonexent is an orally administered small molecule in which salicylic acid and docosahexaenoic acid (DHA) are covalently conjugated through an ethylenediamine linker and -
E646583-25mgEdasalonexent (CAT-1004) is an orally bioavailable NF-κB inhibitor.In VitroEdasalonexent is an orally administered small molecule in which salicylic acid and docosahexaenoic acid (DHA) are covalently conjugated through an ethylenediamine linker and -
E646583-10mgEdasalonexent (CAT-1004) is an orally bioavailable NF-κB inhibitor.In VitroEdasalonexent is an orally administered small molecule in which salicylic acid and docosahexaenoic acid (DHA) are covalently conjugated through an ethylenediamine linker and -
E646583-100mgEdasalonexent (CAT-1004) is an orally bioavailable NF-κB inhibitor.In VitroEdasalonexent is an orally administered small molecule in which salicylic acid and docosahexaenoic acid (DHA) are covalently conjugated through an ethylenediamine linker and
